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Background & Purpose: Allogenic blood transfusion in elective orthopaedic surgery is best avoided owing to
its associated risks. Total knee replacement often requires blood transfusion, more so when bilateral surgery is
performed. Many strategies are currently being employed to reduce the amount of peri-operative allogenic
transfusions. Anti-fibrinolytic compounds such as aminocaproic acid and tranexamic acid have been used
systemically in perioperative settings with promising results. This study aimed to evaluate the effectiveness of
tranexamic acid in reducing allogenic blood transfusion in total knee replacement surgery.
Methodology: This was a retrospective cohort study conducted on patients undergoing total knee replacement
during the time period November 2005 to November 2008. Study population was 99 patients, of which
70 underwent unilateral and 29 bilateral knee replacement. Forty-seven patients with 62 (49.5%) knees (group-I)
had received tranexamic acid (by surgeon preference) while the remaining fifty-two patients with 66 (51.5%)
knees (group-II) had did not received any tranexamic acid either pre- or post-operatively.
Results: The mean drop in the post-operative haemoglobin concentration in Group-II for unilateral and bilateral
cases was 1.79 gm/dl and 2.21 gm/dl, with a mean post-operative drainage of 1828 ml (unilateral) and 2695 ml
(bilateral). In comparison, the mean drop in the post-op haemoglobin in Group-I was 1.49 gm/dl (unilateral) and
1.94 gm/dl (bilateral), with a mean drainage of 826 ml (unilateral) and 1288 ml (bilateral) (p-value < 0.001).
Interpretation: Tranexamic acid is effective in reducing post-operative drainage and requirement of blood
transfusion after knee replacement.
Introduction
Total knee replacement is a frequently done procedure
in modern day practice of any Orthopedics unit. Limit-
ing blood loss both postoperatively and intra-operatively
presents a challenge to the surgeon. Postoperatively,
blood continues to ooze from the cut ends of bone, the
open intra-medullary canal and the raw, dissected soft
tissues. This can amount to significant bleeding with
figures ranging from 600 - 1500 ml [1-7]. As this proce-
dure is performed under tourniquet control, there is an
associated increase in localized fibrinolysis, which
contributes to two events. Firstly, it decreases the risk of
venous thromboembolism and secondly it may aggravate
post-operative haemorrhage [8-10]. The problem of
excessive blood loss is further highlighted in cases of
simultaneous bilateral total knee replacement where
blood loss is usually twice that of a unilateral knee
replacement and the number of allogenic blood units
transfused can be as high as three to four per person
[11,12]. Risks associated with allogenic blood transfusion
are numerous and well documented. Of these the most
important are blood borne infections, immunological
reactions and cost incurred in producing a unit of red
cells [13-15].
Tranexamic acid is an antifibrinolytic agent, which
effectively blocks this fibrinolytic activity, thus causing a
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by blocking the lysine binding sites of plasminogen and
prevents the degradation of fibrin. It has been previously
used quite successfully in urological, gynecological and
thoracic surgical procedures in order to reduce post-
operative blood loss [16-19]. The use of tranexamic acid
in orthopedic surgery has also shown promising results.
It radically reduced both blood loss and the amount of
allogenic transfusions needed postoperatively [9,20-22].
Considering the high risks associated with the use of
allogenic blood, we think that this drug can be very
beneficial to patients undergoing both unilateral and
simultaneous bilateral total knee replacements.
■ The aim of this study was to determine: if the use
of tranexamic acid reduces perioperative blood loss
and need for allogenic blood transfusion in patients
undergoing total knee replacement
■ Any untoward effects with the use of this drug in
our population
Materials and methods
All patients having undergone total knee replacement at
our hospital between November 2005 to November
2008 were included in the study sample.
A total of 99 patients with 128 knee joints were
included in the study. Patients from Group I received
one gram of IV tranexamic acid before inflation of the
tourniquet and 1 g after deflation of tourniquet. Sixty-
six patients (66.4%) underwent unilateral and 23 patients
(24.6%) had bilateral procedures.
All patients with no known bleeding disorders who
under-went TKR were included in our study. All
patients were given routine DVT prophylaxis with Injec-
tion Enoxaparin 40 mg subcutaneous once a day. Anaes-
thesia was standardized and all patients received
epidural anaesthesia according to standard practice.
Patients receiving chronic anticoagulants were excluded
from the study. Haemoglobin was measured preopera-
tively, one hour postoperatively and at 72 hours post-
operatively. The same surgical team performed all
procedures and the same implant (IB-II - Zimmer, War-
saw, IN) was used in all patients. Patellar replacement
was performed in all cases and all components were
cemented.The established practice of transfusion in our
unit is that patients are transfused if:
1. Postoperative Hb is < 7 mg/dl in patients with no
coronary heart disease, or < 9 mg/dl in patients who
have coronary heart disease
2. Physiological signs of inadequate oxygenation such
as hemodynamic instability or symptoms of myocardial
ischemia occur
3. Drainage of more than 1 liter of blood in the first
24 hours
47 patients with 32 (68%) undergoing a unilateral and
15 (32%) undergoing simultaneous bilateral total knee
replacement had received tranexamic acid and these
were labelled as Group-I. Data form Group-I was col-
lected retrospectively by chart review and then com-
pared with that of Group-II which was a historical
control group. Group-II underwent the same procedure
of either a unilateral or simultaneous bilateral total knee
replacements, but did not receive tranexamic acid and
also did not undergo any other procedure to reduce
post-operative bleeding. Patients in both groups were
age and disease-matched. There were 52 patients in
Group-II with 38 (76%) undergoing a unilateral and
14 (24%) undergoing a simultaneous bilateral knee
replacement procedure.
Student t-test was used to compare the means via
SPSS 13.
Results
Mean age of our study population was 59 years [Figure 1].
70% were females and 30% were male patients. Indication
for surgery in 71% of the patients was osteoarthritis while
in 29% of the patients it was rheumatoid arthritis.
The mean drop in the post-operative haemoglobin con-
centration unilateral surgery was 1.49 gm/dl in group Ii
and 1.79 gm/dl in group II, a difference of 17%. for bilat-
eral surgery, the drop was 1.94 gm/dl and 2.21 gm/dl
respectively, a difference of 12%. mean postoperative
blood drainage in unilateral surgery was 826 ml and 1828
ml respectively, a difference of 55%, while in bilateral sur-
gery it was 1288 ml and 2695 ml respectively, a difference
of 52%. Mean drop in the post-operative haemoglobin
concentration and mean post-operative drainage of both
Group-I and Group-II is given in Table 1. Thirty-nine
(75%) out of 52 patients in this Group-II required transfu-
sion. Thirty-two (61.53%) patients required one or two
Figure 1 Age groups.
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required more than two units of transfusion in this group.
In comparison, only 6 (12.76%) out of the 47 patients in
Group-I required blood transfusion and remaining 22
(88.24%) had not required any transfusion. This difference
between the two groups in the number of units of blood
transfused is statistically significant (p-value < 0.001). A
statistically significant (p-value < 0.01) difference in trans-
fusion requirement for patients with Osteoarthritis and
Rheumatoid Arthritis was also noted [Figure 2]. No unto-
ward side effect of tranexamic acid was noted in our
patients.
Discussion
Knowing all the risks and morbidity associated with
allogenic blood transfusion, a surgeon always looks for
ways and means whereby allogenic blood transfusion
can be avoided in surgical patients. The most noticeable,
and extensively explored options available are preopera-
tive blood donation (PAD), acute normovolemic hemo-
dilution (ANH), perioperative red cell salvage (PCS) and
certain anaesthetic techniques (deliberate hypotension,
normothermia) [23]. Certain pharmacological interven-
tions that have been used with success are Recombinant
Human Erythropoietin, tranexamic acid and Aprotinin.
However, none of these agents are without complica-
tions [table 2] and the most important factors to con-
sider in the developing world are the availability and
cost effectiveness of these strategies.
Tranexamic acid, by way of its anti-fibrinolytic action,
prevents clot breakdown and a consequent re-bleed.
Our results demonstrate significant reduction in blood
loss with the use of tranexamic acid. Other studies have
also had similar results [20,22]. A meta analysis which
looked at double blinded randomized controlled trial
also found that tranexamic acid was useful in reducing
blood loss in major orthopedic procedures [24].
No adverse effects were seen in our population with the
use of tranexamic acid. Although side effects have been
reported in other large scale studies but none of them
were serious enough to warrant disuse of the drug [25,26].
In South Asia, apart from poverty, low literacy, social
factors that result in the inability of women to negotiate
safe sex, intravenous drug use and unsafe transfusion is
regarded as one of the most important factors that









Unilateral Bilateral Unilateral Bilateral Unilateral Bilateral
Group-I (N = 47) 826 ml 1288 ml 1.49 g/dl 1.94 g/dl 0.12 0.9 6
Group-II (N = 52) 1828 ml 2695 ml 1.79 g/dl 2.21 g/dl 1.24 2.6 35
p value < 0.001 < 0.001 0.0005 < 0.0005 0.005 0.043
Figure 2 Comparison of transfusion requirement in
Osteoarthritis & Rheumatoid arthritis.
Table 2 Different methods of blood conservation and
their complications




￿ Cardiac, Vasovagal (Risk Factors: Younger
Age, Lower weight, 1
St time donation) [34]
￿ 12 times increase in Anginal and
Vasovagal complications (Risk Factor: 1
st
time donation) [35]
￿ Overall increase frequency of transfusion
(Risk Factor: Lower Preoperative Hematocrit)
[36,37]
￿ Not Cost Effective in Orthopaedic
Procedures [38](More expensive to produce
one unit of autologous blood, Cost also
incurred in disposal of more than half of the
blood discarded which is not used)
Acute Normovolemic
Hemodilution (ANH)
Not effective in Orthopedic Procedures
(data termed inconclusive) [39]
Perioperative red cell
salvage (PCS)
Cost effectiveness of the postoperative
blood collection devices was challenged
(1





haemorrhage, Cardiac Ischemic Injury,
Ischemic Optic neuritis [41-43]
Recombinant Human
Erythropoietin (RHE)
Routine use not justified due to high cost
[44]
Tranexamic acid Very effective [9,20]
Aprotinin ￿ Low dose not effective in orthopedic
procedure [45]
￿ Evidence has been published to suggest
an increase in renal events in patients
given aprotinin when compared to those
where tranexamic acid was used [46]
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quency of viremia due to transfusion-transmitted virus
was observed in most of the study populations from
third world countries, with values ranging from 16 per-
cent in Pakistan to 83 percent in Gambia [29]
A large scale study [30] in Pakistan has shown that the
screening coverage on the average has been 77.42% for
HIV and 86.84% for HBV. The prevalence of HIV is
0.001% and of HBV is 2.259% [30]. The probability of
receiving an infective unit P(R) per 10000 donations is
0.023 for HIV and 29.72 for HBV. The probability of
transmitting infection P (I) per 10000 donations is 0.021
for HIV and 26.75 for HBV. The spreading index for
both viral infections combined is 26.75 per 10000 dona-
tions. Although 80% of joint replacement procedures
take place in the United States and Europe, South Asia
is not far behind with an estimated 40-50 thousand joint
replacement procedures already done yearly in India
alone [31]. Number of knees replaced annually in Paki-
stan is estimated to be 1500-2000 [32].
The cost of one unit of red cells is estimated 120
pounds [14] in Britain while it costs 19.20 British
Pounds in Pakistan [33]. The regimen of tranexamic
acid that was administered in our study population costs
3.75 Pounds. These figures reflect that if one is able to
decrease the requirement of blood by even one unit per
patient the cumulative effect will be a decrease of bur-
den on the health care system. Countries where indivi-
duals pay for their own health care and there is no third
party plan (health insurance companies) involved can
benefit from adopting such cost effective measures.
Although we conducted a retrospective analysis of a
relatively small number patients and the possibility of
the results being affected by recall bias due to historical
c o n t r o l sc a n n o tb er u l e do u ti td o e sp r o v i d et h eb a s i s
for conducting larger scale prospective randomized stu-
dies in order to determine the efficacy of tranxemic acid
in reducing perioperative blood loss.
We believe that the use of tranexamic acid in TKR
surgery is a low cost option in reducing the requirement
of allogenic blood transfusion.
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